Executive Order 14293: Regulatory Relief To Promote Domestic Production of Critical Medicines

What the order contains

Section headings exactly as they appear in the official text.

• Sec. 1. Purpose
• Sec. 2. Policy
• Sec. 3. Streamlining Review of Domestic Pharmaceutical Manufacturing by the Food and Drug Administration
• Sec. 4. Enhancing Inspection of Foreign Manufacturing Facilities
• Sec. 5. Streamlining Review of Domestic Pharmaceutical Manufacturing by the Environmental Protection Agency
• Sec. 6. Centralized Coordination of Environmental Permits to Expand Domestic Pharmaceutical Manufacturing Capacity
• Sec. 7. Streamlining Review of Domestic Pharmaceutical Manufacturing by the United States Army Corps of Engineers
• Sec. 8. General Provisions

Section 1, quoted from the order

Verbatim text from the signed document. These are the words of the document, not SaveYourState’s.

During my first term, my Administration took unprecedented action to improve the well-being of the American people by restoring capacity for domestic production of critical pharmaceutical products. Notably, in Executive Order 13944 of August 6, 2020 (Combating Public Health Emergencies and Strengthening National Security By Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made In The United States), I directed each executive department and agency involved in the procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs to take a variety of actions to increase their domestic procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs, as defined in section 7 of that order, and to identify vulnerabilities in our Nation's supply chains for these products. […]

Federal Register notes

See: EO 13944, August 6, 2020